Does psychedelic-assisted therapy actually work?
Yes, the evidence from clinical trials is strong but limited to controlled research settings. Studies on MDMA-assisted therapy for post-traumatic stress disorder (PTSD) and psilocybin-assisted therapy for major depression have shown these treatments to be highly efficacious, with rapid-acting and durable effects that are also cost-effective [1]. For example, a 2023 review noted that these therapies are resource-intensive but produce lasting improvements [1]. A 2025 paper emphasized that benefits extend beyond symptom relief to enduring changes in self-perception, emotion regulation, and interpersonal connectedness [2]. However, these results come from tightly controlled trials with strict eligibility criteria, not real-world clinical practice [3].
What's holding it back from clinical or public health use?
Several major barriers remain. First, safety concerns: psychedelics can pose risks to individuals with certain medical conditions, such as cardiovascular problems or psychosis, which is why clinical trials use strict medical exclusion criteria [3]. As PAT moves from research to clinics, hospitals must decide how to apply these criteria to ensure safety [3]. Second, ethical and practical issues: a 2023 paper on military settings highlighted unresolved questions about informed consent, confidentiality, and whether patients can return to duty after treatment [1]. Third, the therapy is not just a pill—it requires a structured three-phase process (preparation, administration, and integration) that demands specially trained therapists [2][6]. Fourth, many counselors have mixed attitudes about psychedelics unless they are medically supervised, and the profession has been slow to engage with this treatment model [5]. Finally, regulatory approval has not yet been granted for general clinical use in most countries [1].
Where do researchers disagree or see gaps?
The main disagreement is not about whether PAT works, but about how ready it is for rollout. Some argue that MDMA-assisted therapy is promising enough to be rapidly investigated for specific populations like military service members [1], while others caution that the therapy's unique psychological effects—including profound metaphysical or mystical experiences—require new frameworks for integration and measurement that are not yet established [4]. A 2022 survey found that counselors' attitudes are mixed, with many seeing potential but also needing more evidence [5]. There is also debate about whether the therapy model itself represents a fundamental shift in mental health care that demands reconceptualization, not just a new drug [2]. All papers agree that more research is needed to refine protocols, clarify who is eligible, and train practitioners [1][2][3][6].
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2026, 2 from 2024 or later, 2 in Q1 journals, collectively cited 130 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 38 papers retrieved from a database of over 500 million.
Sources used in this answer
Ethical considerations for psychedelic-assisted therapy in military clinical settings
MDMA- and psilocybin-assisted therapies show high efficacy for PTSD and depression in clinical trials, with rapid, durable, and cost-effective effects, but remain unapproved for general use and raise unique ethical concerns for military populations.
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.
Psychedelic therapy works through serotonergic modulation and neuroplasticity, but its therapeutic benefits also stem from enduring changes in self-perception and emotion regulation, requiring a reconceptualization of mental health treatment.
Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice.
Medical exclusion criteria in clinical trials are designed to minimize risks from psychedelics' physiological effects, and as PAT moves to clinics, hospitals must adapt these criteria for safe practice.
On the need for metaphysics in psychedelic therapy and research
Psychedelic-induced metaphysical experiences should be integrated using philosophical frameworks (a 'Metaphysics Matrix') to enhance therapy, but this approach is not yet standard practice.
Counselors’ attitudes toward psychedelics and their use in therapy
A survey of counselors found mixed attitudes toward psychedelics and PAT, with most supporting medically supervised use but calling for more research and professional engagement.
CE: Psychedelic-Assisted Therapy
Nurses need to learn about psychedelic history, science, and therapy models to prepare for their potential role in PAT as the field develops.